(Last Updated On: November 21, 2018)

Authors: Eunice Kaye M. Rayos-Lopez, MD, Roy Lawrence S. Paredes, MD, Carminda J. Pineda-Rogacion, MD, Carmela Jane C. Luis, MD, Clarisse G. Mendoza, MD, FPDS, Ma. Teresita G. Gabriel, MD, FPDS


Introduction: Bullous Pemphigoid (BP) is a rare disease characterized by autoantibodies directed against BP180 and BP230. For BP patients, disease severity may have an impact on quality of life (QOL). Journals have shown association between disease severity using both Bullous Pemphigoid Disease Area Index (BPDAI) and ELISA Anti-BP180, and using Autoimune Bullous Disease Quality of Life (ABQOL). To date, there is no study correlating BPDAI and ELISA titers with ABQOL among Filipino patients making this the first study to be conducted in the Philippines.

Objectives: To determine if BPDAI and Anti-BP180 levels are correlated with ABQOL among Filipino BP patients.

Methods: Using a retrospective cohort design, charts of patients ≥18 years old from July 2015 to June 2018 were reviewed. Stata MPv14 and Repeated Measures ANOVA was used for analysis and determine changes in variables over time . Reductions were computed for BPDAI and Anti-BP180, and correlated with ABQOL using Pearson’s correlation.

Results: Improvement in BP disease activity was correlated with quality of life. However significant relationships were only observed at month 3 despite the evident improvement in disease activity and quality of life until 6 months.

Conclusion: Patients though improving clinically should have Anti-BP180 monitored at least every 3 months even if lesions are absent, as clinical cure was observed to occur earlier than serologic cure. The presence of both serologic cure and clinical cure is therefore mandatory in the discontinuation of treatment. And ABQOL proved to be an effective tool to ensure best treatment outcomes for BP patient.




Bullous Pemphigoid, BPDAI, ELISA Anti-BP180, ABQOL, quality of life


More Articles

A randomized, double-blind, comparative study on the safety and efficacy of virgin coconut (Cocos nucifera l.) oil against 1% hydrocortisone lotion as an anti-inflammatory and antipruritic preparation for mosquito reactions

  Authors: Uy, Veronica S, MD; Gracia B. Teodosio, MD, FPDS; Ma. Teresita G. Gabriel, MD, FPDS; Mary Catherine T. Galang, MD; Mohammad Yoga A. Waskito, MD; Johannes F. Dayrit, MD, FPDS     Abstract Background: Virgin coconut oil (VCO) has been reported...

read more